RLYB

Rallybio Corporation

1.57 USD
+0.11 (+7.53%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rallybio Corporation stock is up 0.64% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 June’s closed higher than May.

About Rallybio Corporation

Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)